Updated May 2026
Plant medicine,
by the numbers.
What the research actually says. Every figure on this page is linked to a primary source — a peer-reviewed paper, a clinical trial registry, a government report, or an established research organization.
We update this page as new data lands. If you find a number here you'd like to cite, please link to this page rather than re-publishing the data — that's the deal that keeps the lights on.
Section 1 of 6
Psilocybin research
Clinical trials and depression outcomes
Section 2 of 6
Ayahuasca research
Depression, addiction, and neuroimaging data
Section 3 of 6
5-MeO-DMT / Bufo research
The most recently studied of the major psychedelics
Section 4 of 6
Veteran mental health
The crisis driving much of US demand for Mexican retreats
Section 5 of 6
Market and policy
Where the field is going
Section 6 of 6
Mexico-specific
Legal landscape and operational context
How we picked these numbers
We prioritise peer-reviewed sources, then registered clinical trial data, then established research organisations and government reports. Where a statistic exists across multiple sources we link to the most authoritative.
Where a finding is contested or methodology is debated, we say so. Psychedelic research is in an early enthusiasm phase — publication bias, small sample sizes, and difficulty blinding placebo controls are real methodological concerns. We try not to paper over them.
If you spot an error, an outdated number, or a better primary source, please get in touch. Corrections published the same week we receive them.